{
    "nctId": "NCT03650803",
    "briefTitle": "Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer",
    "officialTitle": "Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Assessment of Response to Neo-Adjuvant Chemotherapy in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Utility of Percentage Change in Longitudinal (T1) and Transverse (T2) Relaxation Times From Baseline to First Cycle of Treatment in Assessment of Response to Neo-adjuvant Chemotherapy in Breast Cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Biopsy proven cases of breast cancer\n\nExclusion Criteria:\n\n* Patients with onlybenign lesion\n* Patients with onlyductal carcinomain situ (DCIS)\n* Patients with recurrent/ residual breast cancer in same breast\n* Pregnant women\n* Lactating Women6.Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips.\n* The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator\n* Patients with contraindications for MRIdue to embedded foreign metallic objects. Bullets, shrapnel, metalwork fragments, or other metallic material adds unnecessary risk to the patient.\n* Known history of severe claustrophobia\n* Patients under the age of 18\n* For patients with known history of allergic reaction to MR contrast material or abnormal kidney function (GFR \\< 40 mL/ min), a contrast enhanced exam will not be performed; however, a non-contrast exam may be performed in these patients.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}